Product Code: 978-1-68038-086-6
The global molecular diagnostics market size is expected to reach USD 18.2 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 9.0% over the forecast period. Increasing prevalence of infectious diseases such as influenza and human papillomavirus is projected to be the key factor the growth of the market.
In the underdeveloped regions of Africa, increasing instances of infections such as tuberculosis and HIV have been witnessed in the last few years. This is projected to drive the demand for accurate and early diagnostic techniques to curb the spread of these infections.
Rapid technological advancements-leading to accurate results, portability, and cost-effectiveness-are expected to be a high impact rendering driver for this market. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Companies such as Sigma Aldrich Corporation and Qiagen are developing a new range of molecular diagnostic techniques, such as Transcription-Mediated Amplification (TMA) and Loop-Mediated Isothermal Amplification (LAMP), for the diagnosis of tumors.
Key players in the market are adopting various marketing strategies such as collaborations with technologically advanced companies and diagnostic centers. Furthermore, players are focusing on expanding their geographic presence in order to increase their market share.
Further key findings from the report suggest:
- Reagents dominated the market in 2019 and is also projected to be the fastest-growing product segment owing to its high adoption in research and clinical settings. Standard reagents also provide efficient and accurate results
- Instruments such as next generation sequencing platforms and PCR are increasingly preferred by diagnostic institutes and central laboratories as these tests deliver reliable and quick results and are suitable for a number of diagnostic procedures
- Central laboratories emerged as the leading test location for molecular diagnostics in 2019. This is attributed to the availability of skilled labor and well-established infrastructure
- Point-of-care is expected to be the fastest-growing segment over the forecast period owing to increase in demand for bedside testing, accuracy of results, and rise in healthcare awareness
- Infectious diseases were the largest revenue generating segment in 2019 as molecular diagnostics offer clinicians with better substitutes to diagnose numerous infectious pathogens, bacteria, and virus in a short time while producing extremely accurate results
- The oncology segment is projected to exhibit a CAGR of around 11.3% over the forecast period owing to increasing awareness amongst patients and healthcare professionals regarding available technologies such as molecular testing for cancer diagnosis
- On the basis of technology, PCR was the largest revenue generating segment in 2019 owing to factors such as growing applications of multiplex PCR and commercialization of easy-to-use PCR-based molecular diagnostic kits
- North America was the largest revenue generating region in 2019, followed by Europe. Key factors attributing to their dominance are high patient awareness levels, sophisticated healthcare infrastructure, growing healthcare expenditure, and high R&D pertaining to drug discovery and development
Some of the major players operating in molecular diagnostics market are F. Hoffmann-La Roche Ltd; Siemens Healthcare GmbH; Bio-Rad Laboratories, Inc.; Novartis AG (Grifols); Danaher Corporation; Alere, Inc.; Sysmex Corporation; bioMerieux SA; Becton, Dickinson and Company; Hologic, Inc. (Gen Probe); Johnson & Johnson Services, Inc.; Bayer AG; Cepheid; Dako; and Qiagen.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation
- 1.2 Research Methodology
- 1.3 Research Assumptions
- 1.3.1 Estimates and Forecast Timeline
- 1.4 Research Methodology
- 1.5 Information Procurement
- 1.5.1 Purchased Database
- 1.5.2 GVR's Internal Database
- 1.5.3 Secondary Sources
- 1.5.4 Primary Research
- 1.5.5 Details of Primary Research
- 1.6 Information or Data Analysis
- 1.6.1 Data Analysis Models
- 1.7 Market Formulation & Validation
- 1.8 Model Details
- 1.8.1 Commodity Flow Analysis
- 1.8.1.1 Approach 1: Commodity Flow Approach
- 1.8.1.2 Approach 2: Country wise market estimation using bottom up approach
- 1.9 Global Market: CAGR Calculation
- 1.10 List of Secondary Sources
- 1.11 List of Primary Sources
- 1.12 Objectives
- 1.12.1 Objective 1:
- 1.12.2 Objective 2:
- 1.13 List of Tables
Chapter 2 Executive Summary
Chapter 3 Molecular Diagnostics Market Variables, Trends & Scope
- 3.1 Molecular Diagnostics Market Lineage Outlook
- 3.1.1 Parent market outlook
- 3.2 Penetration & Growth Prospect Mapping
- 3.3 Regulatory and Reimbursement Framework
- 3.4 Market Dynamics
- 3.4.1 Market driver analysis
- 3.4.1.1 Increase in geriatric population
- 3.4.1.2 Introduction of technologically advanced products
- 3.4.1.3 Increase in demand for point-of-care facilities
- 3.4.1.4 Growing prevalence of target diseases
- 3.4.1.5 Increasing external funding for R&D
- 3.4.2 Market restraint analysis
- 3.4.2.1 Presence of ambiguous regulatory framework
- 3.4.2.2 High prices of molecular diagnostics tests
- 3.5 Molecular Diagnostics Market Analysis Tools
- 3.5.1 Porter's Five Forces Analysis
- 3.5.2 SWOT Analysis, By factor (Political & Legal, Economic and Technological)
- 3.5.3 Major deals & strategic alliances analysis
- 3.5.3.1 New product launch
- 3.5.3.2 Mergers and acquisitions
- 3.5.3.3 Expansion
- 3.5.3.4 Partnerships
- 3.5.3.5 Marketing & promotions
- 3.5.3.6 Market entry strategies
Chapter 4 Molecular Diagnostics Market - Competitive Analysis
- 4.1 Recent Developments & Impact Analysis, by Key Market Participants
- 4.1.1 Company/Competition Categorization (Key innovators, Market leaders, Expansion)
- 4.1.2 Innovators
- 4.2 Vendor Landscape
- 4.2.1 List of key distributors
- 4.2.2 Key company market share analysis, 2019
- 4.3 Public Companies
- 4.3.1 Company market position analysis
- 4.3.2 Competitive Dashboard Analysis
- 4.4 Private Companies
- 4.4.1 List of key emerging companies /technology disruptors/innovators
- 4.4.2 Regional network map
Chapter 5 Products Business Analysis
- 5.1 Molecular diagnostics market: Products Movement Analysis
- 5.2 Instruments
- 5.2.1 Instruments market estimates and forecast, 2016 - 2027
- 5.3 Reagents
- 5.3.1 Reagents market estimates and forecast, 2016 - 2027
- 5.4 Others
- 5.4.1 Others market estimates and forecast, 2016 - 2027
Chapter 6 Test Location Business Analysis
- 6.1 Molecular diagnostics market: Test Location Movement Analysis
- 6.2 Point of Care (PoC)
- 6.2.1 PoC market estimates and forecast, 2016 - 2027
- 6.3 Self-testing or OTC
- 6.3.1 Self-testing or OTC market estimates and forecast, 2016 - 2027
- 6.4 Central Laboratories
- 6.4.1 Central Laboratories market estimates and forecast, 2016 - 2027
Chapter 7 Technology Business Analysis
- 7.1 Molecular diagnostics market: Technology Movement Analysis
- 7.2 Polymerase Chain Reaction
- 7.2.1 Polymerase Chain Reaction market estimates and forecast, 2016 - 2027
- 7.2.2 PCR market, by Type
- 7.2.2.1 Multiplex PCR
- 7.2.2.1.1 Multiplex PCR market estimates and forecast, 2016 - 2027
- 7.2.2.2 Other PCR
- 7.2.2.2.1 Other PCR market estimates and forecast, 2016 - 2027
- 7.2.3 PCR market, by Product
- 7.2.3.1 Instruments
- 7.2.3.1.1 Instruments market for PCR estimates and forecast, 2016 - 2027
- 7.2.3.2 Reagents
- 7.2.3.2.1 Reagents market for PCR estimates and forecast, 2016 - 2027
- 7.2.3.3 Others
- 7.2.3.3.1 Others market for PCR estimates and forecast, 2016 - 2027
- 7.3 In Situ Hybridization (ISH)
- 7.3.1 In Situ Hybridization market estimates and forecast, 2016 - 2027
- 7.3.2 Instruments
- 7.3.2.1 Instruments market for ISH estimates and forecast, 2016 - 2027
- 7.3.3 Reagents
- 7.3.3.1 Reagents market for ISH estimates and forecast, 2016 - 2027
- 7.3.4 Others
- 7.3.4.1 Others market for ISH estimates and forecast, 2016 - 2027
- 7.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 7.4.1 INAAT market estimates and forecast, 2016 - 2027
- 7.4.2 Instruments
- 7.4.2.1 Instruments market for INAAT estimates and forecast, 2016 - 2027
- 7.4.3 Reagents
- 7.4.3.1 Reagents market for INAAT estimates and forecast, 2016 - 2027
- 7.4.4 Others
- 7.4.4.1 Others market for INAAT estimates and forecast, 2016 - 2027
- 7.5 Chips and Microarrays
- 7.5.1 Chips and Microarrays market estimates and forecast, 2016 - 2027
- 7.5.2 Instruments
- 7.5.2.1 Instruments market for Chips and microarrays estimates and forecast, 2016 - 2027
- 7.5.3 Reagents
- 7.5.3.1 Reagents market for Chips and microarrays estimates and forecast, 2016 - 2027
- 7.5.4 Others
- 7.5.4.1 Others market for Chips and microarrays estimates and forecast, 2016 - 2027
- 7.6 Mass Spectrometry
- 7.6.1 Mass Spectrometry market estimates and forecast, 2016 - 2027
- 7.6.2 Instruments
- 7.6.2.1 Instruments market for Mass spectrometry estimates and forecast, 2016 - 2027
- 7.6.3 Reagents
- 7.6.3.1 Reagents market for mass spectrometry estimates and forecast, 2016 - 2027
- 7.6.4 Others
- 7.6.4.1 Others market for mass spectrometry estimates and forecast, 2016 - 2027
- 7.7 Sequencing
- 7.7.1 Sequencing market estimates and forecast, 2016 - 2027
- 7.7.2 Instruments
- 7.7.2.1 Instruments market for Sequencing estimates and forecast, 2016 - 2027
- 7.7.3 Reagents
- 7.7.3.1 Reagents market for sequencing estimates and forecast, 2016 - 2027
- 7.7.4 Others
- 7.7.4.1 Others market for sequencing estimates and forecast, 2016 - 2027
- 7.8 Transcription Mediated Amplification (TMA)
- 7.8.1 TMA market estimates and forecast, 2016 - 2027
- 7.8.2 Instruments
- 7.8.2.1 Instruments market for TMA estimates and forecast, 2016 - 2027
- 7.8.3 Reagents
- 7.8.3.1 Reagents market for TMA estimates and forecast, 2016 - 2027
- 7.8.4 Others
- 7.8.4.1 Others market for TMA estimates and forecast, 2016 - 2027
- 7.9 Others
- 7.9.1 Others market estimates and forecast, 2016 - 2027
- 7.9.2 Instruments
- 7.9.2.1 Instruments market for Others estimates and forecast, 2016 - 2027
- 7.9.3 Reagents
- 7.9.3.1 Reagents market for others estimates and forecast, 2016 - 2027
- 7.9.4 Others
- 7.9.4.1 Others market for Others estimates and forecast, 2016 - 2027
Chapter 8 Application Business Analysis
- 8.1 Molecular diagnostics market: Application Movement Analysis
- 8.2 Oncology
- 8.2.1 Oncology market estimates and forecast, 2016 - 2027
- 8.2.2 Breast cancer
- 8.2.2.1 Breast cancer market estimates and forecast, 2016 - 2027
- 8.2.3 Prostate cancer
- 8.2.3.1 Prostate cancer market estimates and forecast, 2016 - 2027
- 8.2.4 Colorectal cancer
- 8.2.4.1 Colorectal cancer market estimates and forecast, 2016 - 2027
- 8.2.5 Cervical cancer
- 8.2.5.1 Cervical cancer market estimates and forecast, 2016 - 2027
- 8.2.6 Kidney cancer
- 8.2.6.1 Kidney cancer market estimates and forecast, 2016 - 2027
- 8.2.7 Liver cancer
- 8.2.7.1 Liver cancer market estimates and forecast, 2016 - 2027
- 8.2.8 Blood cancer
- 8.2.8.1 Blood cancer market estimates and forecast, 2016 - 2027
- 8.2.9 Lung cancer
- 8.2.9.1 Lung cancer market estimates and forecast, 2016 - 2027
- 8.2.10 Other cancers
- 8.2.10.1 Other cancer market estimates and forecast, 2016 - 2027
- 8.3 Pharmacogenomics
- 8.3.1 Pharmacogenomics Market estimates and forecast, 2016 - 2027
- 8.4 Infectious Diseases
- 8.4.1 Infectious Diseases market estimates and forecast, 2016 - 2027
- 8.4.2 Methicillin-resistant Staphylococcus Aureus (MRSA)
- 8.4.2.1 MRSA market estimates and forecast, 2016 - 2027
- 8.4.3 Clostridium difficile
- 8.4.3.1 Clostridium difficile market estimates and forecast, 2016 - 2027
- 8.4.4 Vancomycin-Resistant Enterococci (VRE)
- 8.4.4.1 VRE market estimates and forecast, 2016 - 2027
- 8.4.5 Carbapenem-resistant bacteria
- 8.4.5.1 Carbapenem-resistant bacteria market estimates and forecast, 2016 - 2027
- 8.4.6 Flu
- 8.4.6.1 Flu market estimates and forecast, 2016 - 2027
- 8.4.7 Respiratory Syncytial Virus (RSV)
- 8.4.7.1 RSV market estimates and forecast, 2016 - 2027
- 8.4.8 Candida
- 8.4.8.1 Candida market estimates and forecast, 2016 - 2027
- 8.4.9 Tuberculosis (TB) and drug-resistant TBA
- 8.4.9.1 TB and drug-resistant TB market estimates and forecast, 2016 - 2027
- 8.4.10 Meningitis
- 8.4.10.1 Meningitis market estimates and forecast, 2016 - 2027
- 8.4.11 Gastrointestinal panel testing
- 8.4.11.1 Gastrointestinal panel testing market estimates and forecast, 2016 - 2027
- 8.4.12 Chlamydia
- 8.4.12.1 Chlamydia market estimates and forecast, 2016 - 2027
- 8.4.13 Gonorrhea
- 8.4.13.1 Gonorrhea market estimates and forecast, 2016 - 2027
- 8.4.14 HIV
- 8.4.14.1 HIV market estimates and forecast, 2016 - 2027
- 8.4.15 Hepatitis C
- 8.4.15.1 Hepatitis C market estimates and forecast, 2016 - 2027
- 8.4.16 Hepatitis B
- 8.4.16.1 Hepatitis B market estimates and forecast, 2016 - 2027
- 8.4.17 Other infectious disease market
- 8.4.17.1 Other infectious disease market estimates and forecast, 2016 - 2027
- 8.5 Genetic Testing
- 8.5.1 Genetic Testing Market estimates and forecast, 2016 - 2027
- 8.5.2 Newborn screening
- 8.5.2.1 Newborn screening market estimates and forecast, 2016 - 2027
- 8.5.3 Predictive and Presymptomatic testing
- 8.5.3.1 Predictive and Presymptomatic testing market estimates and forecast, 2016 - 2027
- 8.5.4 Other genetic testing
- 8.5.4.1 Other genetic testing market estimates and forecast, 2016 - 2027
- 8.6 Neurological Diseases
- 8.6.1 Neurological Diseases Market estimates and forecast, 2016 - 2027
- 8.7 Cardiovascular Diseases
- 8.7.1 Cardiovascular Diseases Market estimates and forecast, 2016 - 2027
- 8.8 Microbiology
- 8.8.1 Microbiology Market estimates and forecast, 2016 - 2027
- 8.9 Others
- 8.9.1 Others Market estimates and forecast, 2016 - 2027
Chapter 9 Regional Business Analysis
- 9.1 Molecular diagnostics market: Regional Movement Analysis
- 9.2 North America
- 9.2.1 North America, SWOT Analysis
- 9.2.2 U.S.
- 9.2.3 Canada
- 9.3 Europe
- 9.3.1 Europe, SWOT Analysis
- 9.3.2 U.K.
- 9.3.3 Germany
- 9.3.4 France
- 9.3.5 Italy
- 9.3.6 Spain
- 9.3.7 Belgium
- 9.3.8 Switzerland
- 9.3.9 Netherlands
- 9.3.10 Poland
- 9.3.11 Austria
- 9.3.12 Greece
- 9.3.13 Sweden
- 9.3.14 Turkey
- 9.3.15 Finland
- 9.4 Asia Pacific
- 9.4.1 Asia Pacific, SWOT Analysis
- 9.4.2 India
- 9.4.3 China
- 9.4.4 Japan
- 9.4.5 Sri Lanka
- 9.4.6 Malaysia
- 9.4.7 Australia
- 9.4.8 New Zealand
- 9.4.9 Thailand
- 9.4.10 Vietnam
- 9.4.11 Singapore
- 9.5 Latin America
- 9.5.1 Latin America, SWOT Analysis
- 9.5.2 Mexico
- 9.5.3 Brazil
- 9.5.4 Chile
- 9.5.5 Peru
- 9.5.6 Colombia
- 9.5.7 Argentina
- 9.6 MEA
- 9.6.1 Middle East & Africa, SWOT Analysis
- 9.6.2 South Africa
- 9.6.3 Saudi Arabia
- 9.6.4 Jordan
- 9.6.5 UAE
- 9.6.6 Qatar
- 9.6.7 Nigeria
- 9.6.8 Egypt
Chapter 10 Company Profiles
- 10.1 Market Participation Categorization
- 10.2 Company Profiles
- 10.2.1 Abbott
- 10.2.1.1 Company overview
- 10.2.1.2 Alere, Inc.
- 10.2.1.3 Financial performance
- 10.2.1.4 Product benchmarking
- 10.2.1.5 Strategic initiatives
- 10.2.2 Becton, Dickinson and Company
- 10.2.2.1 Company overview
- 10.2.2.2 Financial performance
- 10.2.2.3 Product benchmarking
- 10.2.2.4 Strategic initiatives
- 10.2.3 bioMerieux SA
- 10.2.3.1 Company overview
- 10.2.3.2 Financial performance
- 10.2.3.3 Product benchmarking
- 10.2.3.4 Strategic initiatives
- 10.2.4 Bio-Rad Laboratories, Inc.
- 10.2.4.1 Company overview
- 10.2.4.2 Financial performance
- 10.2.4.3 Product benchmarking
- 10.2.4.4 Strategic initiatives
- 10.2.5 Agilent Technologies, Inc.
- 10.2.5.1 Company overview
- 10.2.5.2 Financial performance
- 10.2.5.3 Product benchmarking
- 10.2.5.4 Strategic initiatives
- 10.2.6 Danaher Corporation
- 10.2.6.1 Company overview
- 10.2.6.2 Cepheid
- 10.2.6.3 Beckman Coulter
- 10.2.6.4 Leica Biosystems
- 10.2.6.5 Financial performance
- 10.2.6.6 Product benchmarking
- 10.2.6.7 Strategic initiatives
- 10.2.6.8 Strategic initiatives of Cepheid
- 10.2.6.9 Strategic initiatives of Beckman Coulter, Inc.
- 10.2.6.10 Strategic initiatives of Leica Biosystems
- 10.2.7 Hologic, Inc. (Gen Probe)
- 10.2.7.1 Company overview
- 10.2.7.2 Financial performance
- 10.2.7.3 Product benchmarking
- 10.2.7.4 Strategic initiatives
- 10.2.8 Illumina, Inc.
- 10.2.8.1 Company overview
- 10.2.8.2 Financial performance
- 10.2.8.3 Product benchmarking
- 10.2.8.4 Strategic initiatives
- 10.2.9 Johnson & Johnson Services, Inc.
- 10.2.9.1 Company overview
- 10.2.9.2 Financial performance
- 10.2.9.3 Product benchmarking
- 10.2.9.4 Strategic initiatives
- 10.2.10 Novartis (Grifols)
- 10.2.10.1 Company overview
- 10.2.10.2 Financial performance
- 10.2.10.3 Product benchmarking
- 10.2.10.4 Strategic initiatives
- 10.2.11 Qiagen
- 10.2.11.1 Company overview
- 10.2.11.2 Financial performance
- 10.2.11.3 Product benchmarking
- 10.2.11.4 Strategic initiatives
- 10.2.12 F. Hoffmann-La Roche Ltd
- 10.2.12.1 Company overview
- 10.2.12.2 Financial performance
- 10.2.12.3 Product benchmarking
- 10.2.12.4 Strategic initiatives
- 10.2.13 Siemens Healthcare Private Limited
- 10.2.13.1 Company overview
- 10.2.13.2 Financial performance
- 10.2.13.3 Product benchmarking
- 10.2.13.4 Strategic initiatives
- 10.2.14 Sysmex Corporation
- 10.2.14.1 Company overview
- 10.2.14.2 Financial performance
- 10.2.14.3 Product benchmarking
- 10.2.14.4 Strategic initiatives
